Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy

Accept / Decline

Press releases

Ferring Pharmaceuticals acquires novel drug delivery technology from CTCBIO Inc.

Saint-Prex, Switzerland, 23 February 2015 – Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to a novel oral drug delivery technology.

Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin (MINIRIN®) and the fast dissolving lyophilisate (MINIRIN® Melt), is well known. CTCBIO is a growing specialist company that has developed successful manufacturing technologies for more than 30 different drugs, including treatments for dementia and asthma.

"Ferring has been a pioneer in the development of novel oral drug delivery technologies," says Per Falk, MD, PhD, Executive Vice President and Chief Scientific Officer at Ferring, "Our portfolio of peptide therapeutics make us an attractive partner for speciality technology-based companies like CTCBIO to collaborate on new approaches for oral drug delivery of peptides and proteins."

"Keeping the active pharmaceutical ingredient stable and secure is critical," explained Dr. Jeon, Hongryeol, Vice President of CTCBIO. "This technology makes this possible and is particularly useful for hydrophilic macromolecules like peptides and proteins while offering the advantage of oral administration."

Under the agreement involving an undisclosed up-front payment, milestone and royalty terms, the two companies will collaborate to develop prototype formulations for in-vitro and in-vivo testing and the subsequent up-scaling required to manufacture the technology to meet worldwide good manufacturing practice (GMP) requirements.

- ENDS -

About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

MINIRIN and FERRING are trademarks of Ferring B.V.

About CTCBIO Inc.
CTCBIO, INC. operates as a biotechnology company in South Korea and internationally. The company develops pharmaceutical products and food additives. It also develops technology for functional foods and dairy products, as well as provides various bacteria to develop products. The company was founded in 1995 and is headquartered in Seoul, South Korea. (Source: Bloomberg)

For further information:

Ferring media relations:

Helen Gallagher
Tel. +41 (0) 58 301 00 51

Patrick Gorman
Tel. +41 (0) 58 301 00 53

CTCBIO Public relations:

Huikyeong Jeong
Tel: +82 70 4033 0261

See more Press releases



TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10


Global Locator